CD274 and neoplasm: In Arms 1 and 2, the magnitude of pCR and mPR benefit was greater in patients with tumor cell PD-L1 expression ≥ 1% versus < 1%, with the greatest benefit seen in patients with PD-L1 ≥ 50%.